Patent Allowance by Israel Patent Office

Curewize Health Ltd., a diagnostic company focused on the development of proprietary diagnostics for the treatment of Acute Lymphoblastic Leukemia (ALL), announced that the Israeli Patent Authority has indicated on January 24, 2017 that it intends to grant a patent relating to Curewize’s ProALL technology.  The patent will be based on patent application number 224028, which is assigned to Mor Research Applications Ltd. and  licensed to Curewize Health Ltd. The application broadly covers methods of prognosis relating to ProALL technology based on novel methods using micro-RNA for determining prognosis and treatment regimen required by individual patients.